Cite
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
MLA
Langlois, Michel R., et al. “Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM.” Clinical Chemistry & Laboratory Medicine, vol. 58, no. 4, Apr. 2020, pp. 496–517. EBSCOhost, https://doi.org/10.1515/cclm-2019-1253.
APA
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., Collinson, P., Descamps, O. S., Duff, C. J., von Eckardstein, A., Hammerer-Lercher, A., Kamstrup, P. R., Kolovou, G., Kronenberg, F., Mora, S., & Pulkki, K. (2020). Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry & Laboratory Medicine, 58(4), 496–517. https://doi.org/10.1515/cclm-2019-1253
Chicago
Langlois, Michel R., Børge G. Nordestgaard, Anne Langsted, M. John Chapman, Kristin M. Aakre, Hannsjörg Baum, Jan Borén, et al. 2020. “Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM.” Clinical Chemistry & Laboratory Medicine 58 (4): 496–517. doi:10.1515/cclm-2019-1253.